title: [Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration].
abstract: BACKGROUND
  The intravitreal administration of vascular endothelial growth factor (VEGF) inhibitors is the gold standard in the treatment of exudative age-related macular degeneration (AMD) but the possible risks of systemic, particularly cardiovascular side effects are still discussed.
  
  
  METHODS
  We prospectively followed 111 patients at the University Hospital in Göttingen with exudative AMD and intravitreal ocular treatment with bevacizumab and ranibizumab during the upload phase of 3 months using a questionnaire for documentation of possible cardiovascular events.
  
  
  RESULTS
  In 5 out of 111 patients angina pectoris was observed and in 6 patients the antihypertensive medication had to be increased. No differences were found between bevacizumab and ranibizumab. A patient with pre-existing cardiovascular diseases suffered a stroke in the upload phase but no thromboembolic events were observed in the other patients.
  
  
  CONCLUSIONS
  In this small but prospective clinical study no increased risk for cardiovascular events during the upload phase of the VEGF inhibitors ranibizumab and bevacizumab could be detected when taking the age and pre-existing cardiovascular diseases into consideration.
authors.affiliation: Klinik für Augenheilkunde, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland. c.fischer@med.uni-goettingen.de.
authors.forename: C
authors.initials: C
authors.lastname: Fischer
authors.affiliation: Klinik für Augenheilkunde, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Schäfer
authors.affiliation: Immundiagnostik AG, Bensheim, Deutschland.|Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Deutschland.
authors.forename: T
authors.initials: T
authors.lastname: Dschietzig
authors.affiliation: Klinik für Augenheilkunde, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland.
authors.forename: H
authors.initials: H
authors.lastname: Hoerauf
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000139:chemically induced*; D000068258:Bevacizumab / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab / Q000009:adverse effects* / Q000627:therapeutic use*; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Angina pectoris; Cardiovascular side effects; Intravitreal injections; Stroke; VEGF inhibitors